Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MapLight Therapeutics, Inc.MLPT · Entity 5316 | 10% owner | August 14, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MapLight Therapeutics, Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | IndirectSee footnote | 25,306,689 |
Reported balance
After 2026-08-14 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-14 · Purchase · Acquired 4,400,000 · Balance 25,306,689 F1: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | 2,928,686 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Purchase · Acquired 2,928,686 · Balance 2,928,686 F2: The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%. F3: The warrants will not expire until exercised in full. F1: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.
F2: The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%.
F3: The warrants will not expire until exercised in full.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 18, 2026 22:55 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | PurchaseWarrants (right to buy) · Derivative | 2,928,686 | $11.38 Strike: $0.00 | $33,328,153.81 |
DisclosureSEC source: 0001900201-26-000005 · form4-08182026_100832.xml · derivative · entry 2 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,928,686 Underlying: Voting Common Stock · 2,928,686 shares Expires not disclosed F2 · derivative.exercise_date: The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%. F3 · derivative.expiration_date: The warrants will not expire until exercised in full. F1 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| August 14, 2026 Filed Aug 18, 2026 22:55 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | PurchaseVoting Common Stock | 4,400,000 | $11.38 | $50,072,000.00 |
DisclosureSEC source: 0001900201-26-000005 · form4-08182026_100832.xml · nonDerivative · entry 1 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 25,306,689 F1 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| July 30, 2026 Filed Jul 30, 2026 22:39 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | PurchaseVoting Common Stock | 1,000,000 | $13.00 | $13,000,000.00 |
DisclosureSEC source: 0001900201-26-000003 · form4-07302026_100713.xml · nonDerivative · entry 4 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 20,906,689 F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| July 29, 2026 Filed Jul 30, 2026 22:39 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | PurchaseVoting Common Stock | 3,000 | $12.63 | $37,890.00 |
DisclosureSEC source: 0001900201-26-000003 · form4-07302026_100713.xml · nonDerivative · entry 3 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 19,906,689 F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 22:39 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | PurchaseVoting Common Stock | 65,137 | $11.69 | $761,392.91 |
DisclosureSEC source: 0001900201-26-000003 · form4-07302026_100713.xml · nonDerivative · entry 2 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 19,903,689 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.31 to $12.00, inclusive. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 22:39 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | PurchaseVoting Common Stock | 141,088 | $10.74 | $1,515,510.86 |
DisclosureSEC source: 0001900201-26-000003 · form4-07302026_100713.xml · nonDerivative · entry 1 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 19,838,552 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.295 to $11.28, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:16 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | ConversionSeries D Preferred Stock · Derivative | 6,678,910 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 8 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 6,678,910 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F8 · price: The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F8 · derivative.exercise_date: The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F8 · derivative.expiration_date: The Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:16 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | ConversionSeries C Preferred Stock · Derivative | 5,444,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 7 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 5,444,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F7 · price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F7 · derivative.exercise_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F7 · derivative.expiration_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:16 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | ConversionSeries B-1 Preferred Stock · Derivative | 275,148 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 6 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 275,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F6 · price: The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F6 · derivative.exercise_date: The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F6 · derivative.expiration_date: The Series B-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:16 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | ConversionSeries B Preferred Stock · Derivative | 1,263,768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 5 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 1,263,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date. F5 · price: The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date. F5 · derivative.exercise_date: The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date. F5 · derivative.expiration_date: The Series B Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's initial public offering and has no expiration date. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:16 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | ConversionSeries A-1 Preferred Stock · Derivative | 444,846 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 4 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 444,846 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F4 · price: The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F4 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F4 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:16 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | ConversionSeries A Preferred Stock · Derivative | 148,809 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001900201-25-000008 · form4-10292025_081047.xml · derivative · entry 3 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Voting Common Stock · 148,809 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F3 · price: The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F3 · derivative.exercise_date: The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F3 · derivative.expiration_date: The Series A Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:16 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | PurchaseVoting Common Stock | 5,441,176 | $17.00 | $92,499,992.00 |
DisclosureSEC source: 0001900201-25-000008 · form4-10292025_081047.xml · nonDerivative · entry 2 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 19,697,464 F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
| October 28, 2025 Filed Oct 29, 2025 20:16 UTC | MapLight Therapeutics, Inc. MLPT · Entity 5316 | ConversionVoting Common Stock | 14,256,288 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001900201-25-000008 · form4-10292025_081047.xml · nonDerivative · entry 1 Catalyst4, Inc. · CIK 0001900201 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 14,256,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A, A-1, B, B-1, C and D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date. F2 · ownership.nature: The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.